Home About us Contact
|
Home About us Contact | ||
|
|
||
Obliterans Organizing Pneumonia (obliteran + organizing_pneumonia)
Kinds of Obliterans Organizing Pneumonia Selected AbstractsFulminant bronchiolitis obliterans organizing pneumonia following 2 d of treatment with hydroxyurea, interferon- , and oral cytarabine ocfosfate for chronic myelogenous leukemiaEUROPEAN JOURNAL OF HAEMATOLOGY, Issue 1 2004Georgios Kalambokis Abstract:, A 65-yr-old man developed increasing dyspnea and fulminant respiratory failure 48 h after introduction of hydroxyurea, oral cytarabine ocfosfate (YNK01) and interferon- , for treatment of Philadelphia chromosome-positive chronic myelogenous leukemia. The chest radiograph showed bilateral patchy infiltrates while computed tomography revealed multiple bullas, ground glass opacities, and patchy consolidations with possible cavitation. Bronchoscopic examination was normal and microbiological tests performed on all biologic fluids were negative. The patient did not respond to multiple antibiotic treatment and corticosteroid administration and died of progressive respiratory failure 5 d after chemotherapy introduction. The postmortem lung examination was consistent with the diagnosis of bronchiolitis obliterans organizing pneumonia (BOOP). [source] Bronchiolitis obliterans organizing pneumonia as an initial manifestation in systemic lupus erythematosusPEDIATRIC PULMONOLOGY, Issue 3 2005Hidetoshi Takada MD Abstract Bronchiolitis obliterans organizing pneumonia (BOOP) is a rare complication of adult systemic lupus erythematosus (SLE). This is the first report of a pediatric patient with BOOP as an initial presentation of SLE. She had dyspnea, cough, arthralgia, and erythema on her face. Laboratory examinations revealed pancytopenia, low serum levels of complements, and positivity for anti-nuclear antibody, anti-double stranded DNA antibody, and anti-SM antibody. Her respiratory symptoms, pulmonary function tests, and radiologic findings showed significant improvement after treatment with oral prednisolone. Although it is a rare complication among the pleuro-pulmonary manifestations in SLE, BOOP can be the first presentation, even in pediatric patients. © 2005 Wiley-Liss, Inc. [source] Safety of anthrax vaccine: a review by the Anthrax Vaccine Expert Committee (AVEC) of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS)PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, Issue 3 2002John L. Sever Abstract Purpose To assess the safety of a licensed anthrax vaccine given to nearly 400,000 US military personnel, reports of adverse events (AEs) submitted to the Vaccine Adverse Event Reporting System (VAERS) were reviewed and evaluated medically. Methods The Anthrax Vaccine Expert Committee (AVEC), a civilian panel of private-sector physicians and other scientists, reviewed 602 VAERS reports using a Delphic approach (structured expert consensus) to assess the causal relationship between vaccination and the reported AEs and sought to identify unexpected patterns in the occurrence of medically important events. Reports were entered into a database and used to profile AEs with respect to person, type/location, relative frequency, severity/impact, concomitant illness or receipt of other drugs or vaccines, and vaccine lot. Results Nearly half the reports noted a local injection-site AE, with more than one-third of these involving a moderate to large degree of inflammation. Six events qualified as serious AEs (SAEs), and all were judged to be certain consequences of vaccination. Three-quarters of the reports cited a systemic AE (most common: flu-like symptoms, malaise, rash, arthralgia, headache), but only six individual medically important events were judged possibly or probably due to vaccine (aggravation of spondyloarthropathy (2), anaphylactoid reaction, arthritis (2), bronchiolitis obliterans organizing pneumonia) Conclusions Since some cases of local inflammation involved distal paresthesia, AVEC recommends giving subcutaneous injections of AVA over the inferior deltoid instead of the triceps to avoid compression injury to the ulnar nerve. At this time, ongoing evaluation of VAERS reports does not suggest a high frequency or unusual pattern of serious or other medically important AEs. Copyright © 2002 John Wiley & Sons, Ltd. [source] Increased macrophage inflammatory protein-1, and -1, in BAL fluid of bronchiolitis obliterans organizing pneumoniaRESPIROLOGY, Issue 4 2003Toru ASANO Objective: CC chemokines are mainly chemotactic for monocytes and lymphocytes. The aim of this study was to evaluate the involvement of the CC chemokines, macrophage inflammatory protein (MIP)-1, and MIP-1,, in the pathogenesis of bronchiolitis obliterans organizing pneumonia (BOOP). Methodology: The concentrations of MIP-1, and MIP-1, in BAL fluid (BALF) obtained from patients with BOOP (n = 13) and control patients (CP, n= 18) were measured by enzyme-linked immunosorbent assay. Results: MIP-1, in BALF was significantly higher in patients with BOOP (mean ± SD; 123.8 ± 98.0 pg/mL) than in CP (62.5 ± 46.1 pg/mL). Significantly higher MIP-1, was also detected in patients with BOOP (51.6 ± 72.5 pg/mL) than in CP (6.4 ± 3.7 pg/mL). The concentration of MIP-1, significantly correlated with the percentage of lymphocytes in BALF, and the concentration of MIP-1, significantly correlated with the numbers of lymphocytes, neutrophils and eosinophils in BALF. Both MIP-1, and MIP-1, in BALF were decreased after corticosteroid therapy and this was accompanied by decreased lymphocytes in BALF. Conclusion: This study suggests that MIP-1, and MIP-1, may play important roles in the recruitment of immuno-inflammatory cells into the lungs, and may contribute to the pathogenesis of BOOP. [source] Fatal outcome of generalized morphoea with bronchiolitis obliterans organizing pneumoniaCLINICAL & EXPERIMENTAL DERMATOLOGY, Issue 5 2006S. T. Cheung No abstract is available for this article. [source] | ||||||||||